Send the following on WhatsApp
Continue to Chat阿茲海默症認知退化能改善! Eisai 旗下 Lecanemab 於 CTAD 發表三期試驗結果 https://geneonline.news/alzheimer-disease-eisai-lecanemab-ctad-phase-iii-trial/
阿茲海默症認知退化能改善! Eisai 旗下 Lecanemab 於 CTAD 發表三期試驗結果 https://geneonline.news/alzheimer-disease-eisai-lecanemab-ctad-phase-iii-trial/